N. Basté

发表

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Hung-Ming Wang, R. Greil, K. Harrington, 2019, The Lancet.

Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study

V. Moreno, M. Forster, V. Alfaro, 2021, International Journal of Gynecological Cancer.

Transoral laser microsurgery in locally advanced laryngeal cancer: Prognostic impact of anterior versus posterior compartments

M. Bernal-Sprekelsen, I. Vilaseca, J. Berenguer, 2021, Head & neck.

Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score

R. Greil, K. Harrington, I. Braña, 2022, Journal of Clinical Oncology.

SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

Edward S. Kim, M. Stokes, N. Shire, 2019, Journal of Translational Medicine.

Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial

C. García-Girón, R. Hitt, A. Ocaña, 2020, Clinical and Translational Oncology.

Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 1).

J. Giralt, R. Mesía, J. Rodrigo, 2017, Oral oncology.

Association of Physical Activity and Derived Neutrophilto-Lymphocyte Ratio with Outcome in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck Treated with Immunotherapy

I. Vilaseca, J. Berenguer, N. Basté, 2021, Austin Journal of Cancer and Clinical Research.

Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

R. Greil, K. Harrington, A. Psyrri, 2019, Journal of Clinical Oncology.

Persistent lymph nodes after curative chemoradiotherapy for head and neck cancer: imaging predictors of response for decision-making

I. Vilaseca, J. Berenguer, A. Muxi, 2022, European Archives of Oto-Rhino-Laryngology.

Efficacy and safety of immune checkpoint inhibitors in elderly patients (≥70 years) with squamous cell carcinoma of the head and neck.

A. Aupérin, E. Saâda-Bouzid, É. Borcoman, 2019, Journal of Clinical Oncology.

Panitumumab as an effective maintenance treatment in metastatic squamous cell carcinoma of the head and neck.

N. Basté, K. Saleh, C. Even, 2020, Oral oncology.

A retrospective cohort study of PD-L1 expression in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SUPREME-HN).

Edward S. Kim, M. Stokes, N. Shire, 2017 .

CO2-TOLMS for laryngeal cancer in the elderly, pushing the boundaries of partial laryngectomy.

M. Bernal-Sprekelsen, I. Vilaseca, L. Alós, 2022, Oral oncology.

Immunotherapy combinations for the treatment of patients with solid tumors.

G. Recondo, N. Basté, M. Bluthgen, 2020, Future oncology.

New approaches in salivary gland carcinoma

N. Basté, C. Even, M. Classe, 2019, Current opinion in oncology.

Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study

R. Greil, I. Braña, A. Psyrri, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Succinate Pathway in Head and Neck Squamous Cell Carcinoma: Potential as a Diagnostic and Prognostic Marker

R. Bosch, M. Lejeune, J. Vendrell, 2021, Cancers.

Exploratory window-of-opportunity trial to investigate the tumor pharmacokinetcs/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancer.

F. Brichory, P. Rochaix, S. Temam, 2021, Clinical and translational science.

Pembrolizumab (P) or P + chemotherapy (C) versus EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of KEYNOTE-048 by disease state.

R. Greil, K. Harrington, A. Psyrri, 2020 .

Comparison of Treatment Recommendations by Molecular Tumor Boards Worldwide.

Mario Lamping, Ulrich Keilholz, Damian T. Rieke, 2018, JCO precision oncology.

Emerging systemic antitarget treatment for differentiated thyroid carcinoma

M. Mora, N. Basté, J. Grau, 2021, Current opinion in oncology.

SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

Edward S. Kim, M. Stokes, N. Shire, 2019, Journal of Translational Medicine.

Correction to: Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study

M. Juan, N. Viñolas, A. Prat, 2023, Cancer Immunology, Immunotherapy.

KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

R. Greil, K. Harrington, A. Psyrri, 2020 .

Abstract LB-258: Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score <1, 1-19, and ≥20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis

R. Greil, K. Harrington, A. Psyrri, 2020, Bioinformatics, Convergence Science, and Systems Biology.

Non-small cell lung cancer, early stage

L. Bubendorf, T. Yamanaka, M. Okada, 2012 .